The American Society of Hematology (ASH) Annual Meeting is the biggest meeting on the global hematology community’s calendar — and we’re proud to see a significant representation from the Mark Foundation community at this year’s event in Orlando, Florida.
These researchers, supported through programs such as the Emerging Leader Awards and Endeavor Awards, are driving high-risk, high-reward projects spanning the breadth of hematological malignancy—from deciphering the core mechanisms of blood cancer development to engineering next-generation cell and gene therapies. Read on for a selection of presentations and moderated sessions.
Friday, December 5
7-10 a.m.
Satellite Symposium: Beyond Chemotherapy: Patient Voices and Expert Insights on Using Precision Therapies to Enhance Personalized Care of Follicular Lymphoma
Speaker: Mitchell Smith, MD, PhD, The Follicular Lymphoma Foundation (Mark Foundation partner organization)
Hyatt – Regency Ballroom R
11 a.m.-2 p.m.
Satellite Symposium: Medical Crossfire®: Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care
Speaker: ASPIRE Awardee Claire Roddie, MD, PhD, University College London
OCCC – Tangerine Ballroom F1
11 a.m.-2 p.m.
Satellite Symposium: Advancing Outcomes in Lymphoma Care: A Master Class on Integrating the CAR T-Cell Therapies into Clinical Practice
Speaker: Endeavor Awardee Michael Jain, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute
Hyatt – Regency Ballroom OPQ
1:30-2 p.m.
Blood Drops: PhD (Transitioning to Independence)
Speaker: Momentum Fellow Florian Perner, MD, Hannover Medical School, Germany
SeaWorld Sea Harbor Pavilions, Plaza – Station 5
2:40-3:10 p.m.
Blood Drops: Career Development and Tips on Job Searching and Negotiation (for PhDs, Clinicians, etc.)
Speaker: Mark Foundation-Gabrielle’s Angel Foundation Awardee Shannon Elf, PhD, University of Chicago
SeaWorld Sea Harbor Pavilions, Plaza – Station 3
3-6 p.m.
Satellite Symposium: Bridging the Gaps in CAR T-Cell Therapy for Hematological Malignancies: Expert Guidance, Clinical Experience and Increased Access
Speaker: Endeavor Awardee Marco Davila, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute
OCCC – W230
3-6 p.m.
Scientific Workshop: Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
Co-chair: Mark Foundation-RUNX1 Research Program Awardee Lucy Godley, MD, PhD, University of Chicago
OCCC – W307
3-6 p.m.
Scientific Workshop: Mitochondria and Metabolism in Blood Cancer and Normal Hematopoiesis- From Discovery to Patients
Co-chair: Drug Discovery Awardee Aaron Schimmer, MD, PhD, Princess Margaret Cancer Centre
OCCC – W414AB
3-6 p.m.
Scientific Workshop: Therapy Resistance Mechanisms in Blood Malignancies
Co-chair: Mark Foundation-Leukemia & Lymphoma Society-Paul G. Allen Frontiers Group Awardee Daniel Starczynowski, PhD, Cincinnati Children’s Research Foundation
OCCC – W414CD
3-6 p.m.
Scientific Workshop: State of the Art: Integrating Functional and Genomic Precision Medicine for Hematologic Malignancies
Speaker: Emerging Leader Award winner Jeffrey Tyner, PhD, Oregon Health and Science University
OCCC – W308
3:06-3:48 P.m.
Scientific Workshop: Disease Models and Mechanisms: Bridging the Gap
Speaker: Endeavor Awardee Stanley Lee, PhD, Fred Hutchinson Cancer Center
Presentation: Uncovering the Pathogenic Mechanisms of DDX41 Mutations in Myeloid Malignancies
OCCC – W307
Saturday, December 6
12-1:30 p.m.
Oral Abstract Session: Lymphoid Oncogenesis: Basic – Mechanistic studies of lymphoid leukemias and lymphomas
Moderator: ASPIRE Awardee (in partnership with the Follicular Lymphoma Foundation) Coraline Mlynarczyk, PhD, Yale School of Medicine and Yale School of Engineering & Applied Science
OCCC – W224ABEF
2-3:15 p.m.
Scientific Program: Innovative Models of Lymphoma
Speaker: ASPIRE Awardee (in partnership with the Follicular Lymphoma Foundation) Michael R Green, PhD, The University of Texas MD Anderson Cancer Center
Presentation: Utilizing Refined Lymphoma Models for Treatment Studies: Innovations in Syngeneic Transplants, Patient-Derived Xenografts, and Humanized Mouse Model
OCCC – West Hall E2
Sunday, December 7
9:30-11:05 a.m.
Joint Session: Game of Clones – The Evolution of Hematopoiesis from Birth to Aging
Speaker: Mark Foundation-Gabrielle’s Angel Foundation Awardee Grant Challen, PhD
Presentation: Genetic-Epigenetic Regulators Providing a Competitive Advantage to HSCs
OCCC – W312
12-1:30 p.m.
Oral Abstract Session: Lymphomas: Translational – Non-Genetic: T cell interactions in the lymphoma microenvironment – the good and the bad
Speaker: Endeavor Awardee Marco Davila, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute
Presentation: CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma
OCCC – Tangerine Ballroom F1
12:30-1:30 p.m.
ASH-EHA Joint Symposium: Menin Inhibitors: Novel Targeted Agents for Treatment of Acute Myeloid Leukemia (AML)
Speaker: Mark Foundation Scientific Advisory Committee Member Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute
Presentation: Design and Development of Menin Inhibitors, Mechanisms of Action, Clinical Trial Results, and Safety
OCCC – West Hall D2
4:30-6 p.m.
Oral Abstract Session: Myelodysplastic Syndromes: Basic and Translational: Mechanisms of MDS Initiation and Progression
Co-Moderator: Endeavor Awardee Brent Ferrell, MD, Vanderbilt University Medical Center
OCCC – Valencia Room W415A
4:30-6 P.m.
Oral Abstract Session: Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies
Presenter: Emerging Leader Award winner Andrew Lane, MD, PhD, Dana-Farber Cancer Institute
Presentation: Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial
OCCC – Chapin Theater (W320)
5:30-7:30 p.m.
Poster Abstract Session: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
Author: ASPIRE Awardee Kara Davis, DO, Stanford University
Poster: Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results
OCCC – West Halls B3-B4
6-8 p.m.
Poster Abstract Session: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
Author: Endeavor Awardee Marco Davila, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute
Posters:
In-depth, quantitative characterization of important regulators and predictive biomarkers for CAR T-cell therapy-induced toxicities in a clinical cohort
CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy
OCCC – West Halls B3-B4
Monday, December 8
2:45-4 p.m.
Scientific Symposium: Targeting Cancer Metabolism – Innovative Methods to Translation
Speaker: Endeavor Awardee Jeffrey Rathmell, PhD, University of Chicago
Presentation: Metabolic Sources of Immune Cell Dysfunction
OCCC – W312
Be sure to check the official conference website for updates, additional presentations, and dozens of abstracts from our grantees!
See someone missing from this list? Drop us a note at info@themarkfoundation.org.